Actuate Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Actuate Therapeutics, Inc. - overview
Established
2015
Location
Fort Worth, TX, US
Primary Industry
Pharmaceuticals
About
Founded in 2015 and based in Texas, US, Actuate Therapeutics, Inc. is a biopharmaceutical company that engages in the research and development of compounds for the treatment of cancer and inflammatory diseases that lead to fibrosis and neurodegeneration. As of 2024, the company is headed by its CEO Daniel M. Schmitt.
In August 2024, the firm raised USD 22. 400 million in an IPO, selling 2. 80 million shares at USD 8 per share, below the expected USD 8-10 range, on the Nasdaq Global Select Market under the ticker symbol "ACTU. " Actuate Therapeutics, Inc.
has granted the underwriters a 30-day option to purchase up to an additional 420,000 shares of common stock as part of the listing. Following the transaction, Bios Equity, and Kairos Venture retained a minority stake in Actuate Therapeutics, Inc. , respectively. Actuate's primary product, elraglusib, is a novel GSK-3 inhibitor that targets multiple molecular pathways associated with cancer growth and resistance.
This drug is designed to address the limitations of traditional chemotherapy by inhibiting key immune checkpoints and regulating immune cell function. It provides cancer therapeutics with a focus on both tumor reduction and immune system modulation. Actuate Therapeutics is in the research and development phase, with revenue primarily generated through investment and partnerships. The company is supported by funding from investors and collaborative agreements with academic and scientific organizations.
Current Investors
DEFTA Partners, Bios Partners, Tech Coast Angels
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.actuatetherapeutics.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
Actuate Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPO | Completed | Actuate Therapeutics, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.